ライフサイエンスコーパス: coagulant

1 ein was similar to that of a commercial milk coagulant.

2 ng ferric chloride, a common water treatment coagulant.

3 moved a humic-like group irrespective of the coagulant.

4 RNOM, Ca(2+) does not always act as a strong coagulant.

5 lecule in widespread clinical use as an anti-coagulant.

6 rentiate it from cheeses produced with other coagulants.

7 with polyaluminum chloride or ferric sulfate coagulants.

8 III (wt-fVIII) demonstrated similar specific coagulant activities but poor secretion of N1922S-fVIII.

9 nt with the bleeding disorder, the factor IX coagulant activities for wild-type (+/+), heterozygous (

10 Asn(2181) in human FV(a1) and have different coagulant activities.

11 t mediator of their pro-inflammatory and pro-coagulant activities.

12 a level of factor VII antigen and factor VII coagulant activity (<1 percent of normal) and suffers fr

13 prothrombin 20210A, and elevated factor VIII coagulant activity (factor VIII:c), these odds ratios we

14 ypotheses that elevated levels of factor VII coagulant activity (FVII:C), fibrinogen, and von Willebr

15 activated factor XII (FXIIa), and factor VII coagulant activity (FVIIc) are associated with higher ri

16 , 1.35, and 1.15 (P:<0.0001); for factor VII coagulant activity (FVIIc, % standard), 114.5, 116.2, an

17 Plasma factor VIII coagulant activity (FVIII:C) level is a highly heritable

18 rations (r = 0.48, P = 0.008) and factor VII coagulant activity (r = 0.46, P = 0.012) after adjustmen

19 on in the F7 gene that results in factor VII coagulant activity (VII:c) of less than 1% and VII antig

20 count (men, 1.68; women, 2.23), factor VIII coagulant activity (women, 1.25), and von Willebrand fac

21 ustained therapeutic expression of factor IX coagulant activity after gene transfer in 10 participant

22 in vivo with significantly reduced factor IX coagulant activity and a marked prolongation of the acti

23 ulation of adhesion molecule expression, pro-coagulant activity and inhibition of Toll-like receptor

24 The specific coagulant activity and the in vivo clearance and hemosta

25 ng concentrations of FVIIa exhibited similar coagulant activity as that of wild-type TF.

26 ivation, but also as a direct inducer of pro-coagulant activity associated with vascular and thrombot

27 Transgene-derived factor IX coagulant activity enabled the termination of baseline p

28 isplayed impaired adhesion, aggregation, and coagulant activity ex vivo that translated into defectiv

29 We further show that PDI suppresses TF coagulant activity in a nitric oxide-dependent pathway,

30 n 10 men with hemophilia B who had factor IX coagulant activity of 2% or less of the normal value.

31 , with a mean (+/-SD) steady-state factor IX coagulant activity of 33.7+/-18.5% (range, 14 to 81).

32 The coagulant activity of IXaWT was approximately 93%, of IX

33 inhibit endotoxin-induced tissue factor pro-coagulant activity of U937 cells.

34 apple domain (factor XI/PKA3) had <1% of the coagulant activity of wild type factor XIa in a plasma c

35 sulted in reduced adhesion, aggregation, and coagulant activity on collagen in vitro.

36 PDI enhanced TF coagulant activity on microvesicles shed from cells, sug

37 or VIIIa affinity and dramatically increased coagulant activity relative to factor IXa WT.

38 wed a 6- to 17-fold enhanced proteolytic and coagulant activity relative to mFVIIa, but increased ina

39 spholipid, FXI/PKA4 and FXI/PKA4-Gly326 have coagulant activity similar to FXI.

40 ments contained higher TF protein levels and coagulant activity than equivalent linear areas.

41 rom inactivation/inhibition; (3) restricting coagulant activity to the site of vascular injury; and (

42 Its coagulant activity was enhanced in all types of plasma a

43 Coagulant activity was moderately (N129A, K132A, K126A)

44 Factor IX coagulant activity was normal in samples from donors wit

45 Vector-derived factor IX coagulant activity was sustained in all the participants

46 antigen (VWF:Ag), multimers, and factor VIII coagulant activity were virtually absent.

47 s soluble, circulates in blood, exhibits pro-coagulant activity when exposed to phospholipids, and is

48 is equivalent to about a 5-fold increase in coagulant activity when stimulated platelets are compare

49 ke is an important determinant of factor VII coagulant activity, a hemostatic risk factor for fatal i

50 w patients with isolated defects in platelet coagulant activity, and compared with that in Scott synd

51 gl2 is IFN gamma-inducible, possesses direct coagulant activity, and inhibits T cell proliferation an

52 of the heat treatment and levels of residual coagulant activity, breakdown of proteins and formation

53 related to defective expression of membrane coagulant activity, circulating blood cells show decreas

54 ibited both EMT-associated TF expression and coagulant activity, further strengthening the link betwe

55 n III, an endogenous inhibitor of thrombin's coagulant activity, is an equally effective inhibitor of

56 Although the polysaccharide showed some anti-coagulant activity, small oligosaccharide fCS fragments

57 Cl(2) markedly increased the cell-surface TF coagulant activity, the increase is associated with incr

58 either type 1 immunity or immune-associated coagulant activity.

59 use APC seemed to be independent of its anti-coagulant activity.

60 f the A3 domain markedly decreased factor XI coagulant activity.

61 factor (TF) and exhibited similar extrinsic coagulant activity.

62 c phospholipids, attenuated the increased TF coagulant activity.

63 1), or fibrinogen concentrations; factor VII coagulant activity; or plasminogen activator inhibitor t

64 loop of IXaE245V with a concomitant loss of coagulant activity; this proteolysis was moderate in IXa

65 The influence of simultaneous coagulant addition on PAC adsorption of micropollutants

66 reference for this moiety was supported by a coagulant-affinity factor derived from the association b

67 gnificantly with the inclusion of an anionic coagulant aid and slightly with a cationic coagulant aid

68 c coagulant aid and slightly with a cationic coagulant aid.

69 igated to determine the effects of different coagulant aids (anionic, cationic, and nonionic polymers

70 It was shown that coagulants and coagulant aids applied to OSPW feedwater can affect memb

71 Among three coagulant aids tested, anionic coagulant aids led to the most enhanced membrane perform

72 OSPW turbidity, the application of cationic coagulant aids promoted the adsorption of foulants on me

73 Among three coagulant aids tested, anionic coagulant aids led to the

74 Conversely, although cationic coagulant aids were the most effective in reducing OSPW

75 rgoes proteolytic irreversible activation by coagulant and anti-coagulant proteases.

76 roprotective effect is secondary to its anti-coagulant and anti-inflammatory effects.

77 Activated protein C (APC) is a systemic anti-coagulant and anti-inflammatory factor.

78 A timely institution of anti-coagulant and anti-tubercular treatment led to a complet

79 nciples of proteolytic cell signaling of the coagulant and anticoagulant pathways.

80 receptor that elicits cellular responses to coagulant and anticoagulant proteases.

81 s perinecrotic regions were enriched for pro-coagulant and DNA damage response proteins.

82 The coagulant and hemostatic effects of rFIX and pdFIX were

83 The coagulant and inflammatory exacerbation in sepsis is cou

84 ibition of APC function exacerbates both the coagulant and inflammatory responses of the animals to s

85 o bacterial challenge, exacerbating both the coagulant and inflammatory responses.

86 ve TGF-beta(1) concentrations and factor VII coagulant and plasminogen activator inhibitor type 1 act

87 As they are pro-coagulant and potentially pro-inflammatory, rapid cleara

88 otein disulfide isomerase (PDI) regulates TF coagulant and signaling activities by targeting this dis

89 It was shown that coagulants and coagulant aids applied to OSPW feedwater

90 an those of commonly applied iron-containing coagulants and the formation of ferrimagnetic species pr

91 on parameters of lung AR relate to the anti-coagulant, anti-inflammatory, and possibly immunoregulat

92 cological perturbations of the intravascular coagulant balance were combined with genetic mouse model

93 ereas rPAR1(T) is not a substrate for weakly coagulant beta-thrombin.

94 The type of coagulant (bovine or vegetable) had no significant effec

95 In contrast, the anti-inflammatory/anti-coagulant CD141/thrombomodulin increased markedly when I

96 r study comparing 6 months of anti-inhibitor coagulant complex (AICC), infused prophylactically at a

97 hemostasis proceeds through the assembly of coagulant complexes on a lipid surface derived from acti

98 Optimum coagulant concentration (OCC) decreased with increasing

99 ased aggregation rate and increased critical coagulant concentration required for diffusion-limited a

100 In addition to IL-1beta, pro-coagulant concentrations of thrombin or fresh platelets

101 PKA did not correct the coagulant defect in factor XII deficient plasma, was pur

102 Accordingly, the coagulant demand increased by 1.5 and 3.8x for the water

103 Prophylactic anti-coagulants did not affect symptomatic central venous thr

104 onal strategy to deliver locally-active anti-coagulants directly within grafts and decrease microvasc

105 lly removed humic substances and reduced the coagulant dose needed for colloidal NOM removal as a res

106 ctively remove colloidal NOM and the optimal coagulant dose was primarily determined by the concentra

107 resholds for color, total organic carbon and coagulant dose.

108 X and coagulation pretreatment at much lower coagulant doses was as effective as coagulation in reduc

109 emical and electrodissolution contributed to coagulant dosing since measured aluminum concentrations

110 both unliganded and in complex with the anti-coagulant drug warfarin.

111 ic activity was inhibited by dicumarol, anti-coagulant drug, with IC50 of 4 microm.

112 Although commonly used anti-coagulant drugs, such as low molecular weight heparin an

113 rs showed that the aPL mAbs reduced the anti-coagulant effect of annexin A5 and promoted thrombin gen

114 which activates deleterious inflammatory and coagulant effector mechanisms, is an effective molecular

115 y higher avidity binding to FXa with greater coagulant effects compared to systemic lupus erythematos

116 The coagulant effects of PDI inhibition were sensitive to an

117 suitability of a PARAFAC-based approach for coagulant evaluation/selection was demonstrated when com

118 er self-proteins involved in inflammatory or coagulant events.

119 including the binding constants (Kd) of the coagulant factors for the lipid surface.

120 ression while inducing the expression of pro-coagulant factors.

121 cell shrinkage occurring in the presence of coagulant fixative.

122 Although the size of nano-scale primary coagulant flocs changed little by the addition of NaClO,

123 enhances the bonding with, and between, the coagulant flocs; EPS together with smaller sizes of the

124 imidazole (APIm) is proposed as a reversible coagulant for harvesting microalgae.

125 ur results demonstrated that PGA is a potent coagulant for the coacervation of 7S, 11S, daidzein and

126 DOM) in a multicoagulant (two aluminum-based coagulants) full scale drinking water treatment plant.

127 ivary-expressed apyrases, which have an anti-coagulant function in blood-feeding arthropods.

128 Xa activation of PAR-1 but does not enhance coagulant function of factor Xa.

129 antigen levels >40% in the absence of FVIII coagulant function were detected in the circulation for

130 ibrinolytic activity and lipemia, factor VII coagulant (FVII:c) activity, and activated FVII (FVIIa)

131 activated factor VII activity (FVIIa), FVII coagulant (FVIIC) activity, FVIII coagulant (FVIIIC) act

132 enotype is a major determinant of factor VII coagulant (FVIIc) activity, which is associated with an

133 IIa), FVII coagulant (FVIIC) activity, FVIII coagulant (FVIIIC) activity, tissue factor pathway inhib

134 rom plant sources have been proposed as milk coagulants, however, limited research has been done on t

135 us hold the best potential for use as a milk coagulant in cheese production.

136 pis procera extract can be used as effective coagulant in cheesemaking.

137 Not only was this coagulant increase costly for the utility, it also resul

138 an endogenous inhibitor of factor Xa and the coagulant initiator complex tissue factor/factor VIIa.

139 n 2 (CFHR2, related to complement system and coagulant mechanism) were selected for further ELISA val

140 Both alpha-thrombin and weakly coagulant meizothrombin-des-fragment-1 (mu-thrombin) hyd

141 sel-Ig contained higher concentration of pro-coagulant microparticles and clotted one minute faster t

142 irculates, although it may be present in pro-coagulant microparticles.

143 UMC > 0.98), and a comparable effect of both coagulants on the structure (UMC > 0.99) and distributio

144 he gene silencing had no effect on either TF coagulant or cell signaling functions.

145 at the cross-roads of both the pro- and anti-coagulant pathways.

146 Pretreating organs with novel cytotopic anti-coagulant peptides that localise to endothelial cell mem

147 This pro-coagulant phenotype of DeltaCT mice could be reversed by

148 ighlights the potential use of a phosphonium coagulant polymer, polyDADEPC, as a viable alternative t

149 roenvironment of the sacrificial anode where coagulant precursors are dissolved leading to better des

150 transfusion practices for both platelets and coagulant products (e.g., fresh-frozen plasma and recomb

151 PC functions as an anti-coagulant, profibrinolytic, and anti-inflammatory agent,

152 er complex was generated, which explains the coagulant properties and efficient Fbg conversion.

153 en C19MC oncogenic miRNAs (oncomirs) and the coagulant properties of cancer cells, a question previou

154 EMT transcription factor Snail increased TF, coagulant properties, and early metastasis.

155 Activation of PAR1 by the coagulant protease thrombin results in Ras homolog gene

156 (PAR1), a G protein-coupled receptor for the coagulant protease thrombin, is irreversibly activated b

157 a G-protein-coupled receptor (GPCR) for the coagulant protease thrombin.

158 AR1) is a G protein-coupled receptor for the coagulant protease thrombin.

159 s activated by thrombin whereas the upstream coagulant protease VIIa bound to tissue factor and Xa ca

160 Activated protein C (APC), an anti-coagulant protease, also activates PAR(1).

161 Thrombin, a coagulant protease, induces inflammatory responses and e

162 eceptors that transmit cellular responses to coagulant proteases in a variety of cell types in the va

163 and functions as the endogenous receptor for coagulant proteases VIIa and Xa in these cells.

164 rs that function as cell-surface sensors for coagulant proteases, as well as other proteases associat

165 rreversible activation by coagulant and anti-coagulant proteases.

166 blood coagulation factor IX (hFIX) and anti-coagulant protein C (hPC) genes, previously shown to hav

167 inhibitors directed against the factor VIII coagulant protein is one of the most challenging and exp

168 er are to produce therapeutic amounts of the coagulant protein while minimizing an immune response or

169 equire lipolysis and the presence of another coagulant protein, factor IX.

170 n thrombin-induced thromboembolism, factor X coagulant protein-induced thrombosis, and endotoxin-indu

171 Thrombin and factor Xa, two important pro-coagulant proteinases, can be regulated through direct a

172 eparation using centrifugation for dissolved coagulant recovery.

173 ted that the Procr+/- genotype increased the coagulant response relative to wild-type mice.

174 They also exhibited a similar coagulant response upon factor Xa/phospholipid infusion.

175 ence protein C activation and exaggerate the coagulant response.

176 t protease inhibitor in the inflammatory and coagulant responses to septic illness have not been eval

177 Thrombin is a pro-coagulant serine protease, which causes the local loss o

178 on capacity associated with higher available coagulant surface area, (iii) greater virus-floc binding

179 lex interaction between the inflammatory and coagulant systems in sepsis pathophysiology has resulted

180 nary TF-FVIIa-FXa complex but not by the non-coagulant TF-FVIIa binary complex.

181 rotein carboxylation and Warfarin-based anti-coagulant therapies that need to be considered both retr

182 travascular thrombin concentrations exceed a coagulant threshold.

183 As expected, the mean F.IX coagulant titer of affected male mice was 2.8 U/dL (n =

184 environmental processes and in the action of coagulants used in water and wastewater treatment.

185 ently the optimal temperature of immobilized coagulant was defined and a technically-friendly enzyme

186 Cancer pro-coagulant was localized to tumor cells in several cases

187 The recovered coagulant was then reused for treating primary wastewate

188 sludge and its reuse potential as secondary coagulant were investigated.

189 olytics, and down-regulation of natural anti-coagulants, with protein C (PC) being a critical example